Zentalis Pharmaceuticals, Inc. (ZNTL) Dividend History

Company News

• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Zentalis Pharmaceuticals granted stock options to four newly hired employees as an inducement to join the company. The options have a 10-year term and will vest over four years.

  GlobeNewswire Inc.
• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted non-qualified stock options to three newly hired employees as an inducement to join the company.

  GlobeNewswire Inc.
• Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

  Zentalis Pharmaceuticals presented updated clinical data on its WEE1 inhibitor azenosertib, which demonstrated promising anti-tumor activity and durable responses in patients with platinum-resistant ovarian cancer. The company plans to initiate a registration-intent study in 2025 and expects topline data by 2026.

  GlobeNewswire Inc.
• Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted non-qualified stock options and restricted stock units to a newly hired employee as an inducement to join the company.

  GlobeNewswire Inc.
• Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted non-qualified stock options to a newly hired employee as an inducement to join the company.

  GlobeNewswire Inc.